0000000000240257

AUTHOR

Jordi Rodon

showing 2 related works from this author

Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)

2018

Oncologymedicine.medical_specialtyMolecular screeningbusiness.industryAdvanced breastCancerHematologymedicine.diseaseBreast cancerOncologyInternal medicinemedicineAGATAbusinessAnnals of Oncology
researchProduct

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in p…

2011

Abstract Purpose: Insulin-like growth factor-1 receptor (IGF-1R) mediates cellular processes in cancer and has been proposed as a therapeutic target. Dalotuzumab (MK-0646) is a humanized IgG1 monoclonal antibody that binds to IGF-1R preventing receptor activation. This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose. Experimental Design: Patients with tumors expressing IGF-1R protein were allocated to dose-escalating cohorts of three or more patients each and received intravenous dalotuzumab weekly, every 2 or 3 weeks. Plasma was collected for PK analysis…

AdultMaleCancer ResearchMaximum Tolerated Dosemedicine.medical_treatmentAntineoplastic AgentsPharmacologyAntibodies Monoclonal HumanizedDrug Administration ScheduleReceptor IGF Type 1Insulin-like growth factorPharmacokineticsNeoplasmsmedicineHumansAgedAged 80 and overDose-Response Relationship DrugDalotuzumabbusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseOncologyTolerabilityPharmacodynamicsMonoclonalToxicityFemalebusinessClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct